NCT05272371View on ClinicalTrials.gov

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
High-Risk Neuroblastoma
Interventions
COMBINATION_PRODUCT

Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)

Dinutuximab beta in combination with chemotherapy.

Trial Locations (1)

30-663

RECRUITING

University Children Hospital, Krakow

All Listed Sponsors
lead

Jagiellonian University

OTHER